News & Updates
Filter by Specialty:
Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC
Updated results of the DESTINY-Breast03 trial, presented at SABCS 2022, showed that in patients with HER2+ metastatic breast cancer, second-line treatment with trastuzumab deruxtecan conferred better survival benefits than treatment with trastuzumab emtansine.
Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC
20 Jan 2023
Signs of heavy menstrual bleeding often missed; standardized criteria for assessment needed
Healthcare professionals (HCPs) and women themselves may overlook the signs of heavy menstrual bleeding, with most HCPs failing to recognize the key indicators for bleeding disorders and perform assessments for patients with heavy menstrual bleeding, according to a study presented at ASH 2022.
Signs of heavy menstrual bleeding often missed; standardized criteria for assessment needed
20 Jan 2023
TNFα antagonists, non-TNF biologics both safe for treating IBD in cancer patients
Tumour necrosis factor (TNF)-α antagonists show comparable safety as non-TNF biologics in the treatment of inflammatory bowel disease (IBD) in patients with active or recent cancer, as shown in a study.
TNFα antagonists, non-TNF biologics both safe for treating IBD in cancer patients
20 Jan 2023
POSEIDON: Dual ICIs plus chemo up survival in first-line mNSCLC
POSEIDON: Dual ICIs plus chemo up survival in first-line mNSCLC
20 Jan 2023
Total diet replacement shows promise for difficult-to-treat asthma
A low-calorie total diet replacement program (Counterweight-Plus) is safe and improves asthma control and quality of life in patients with difficult-to-treat asthma and obesity, according to 16-week data from a recent study.